Squamous Cell Carcinoma of the Oropharynx Clinical Trial
Official title:
Volume and Dose De-Intensified Radiotherapy for p16+ Squamous Cell Carcinoma of the Oropharynx: A Multi-Centre, Single Arm Prospective Cohort Study
Volume and Dose De-Intensified Radiotherapy for p16+ Squamous Cell Carcinoma of the Oropharynx: A Multi-Centre, Single Arm Prospective Cohort Study
De-intensified radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Omission of level IB lymph node regions from the elective nodal volumes. Chemotherapy will be administered as per standard of care, consisting of concurrent cisplatin (high-dose: 100mg/m2 IV every 3 weeks or low-dose: 40mg/m2 IV every week) or cetuximab (at the discretion of medical oncologist). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03669718 -
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
|
Phase 2 | |
Withdrawn |
NCT01586182 -
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04151134 -
Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning
|
||
Not yet recruiting |
NCT06380686 -
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
|
||
Recruiting |
NCT05119036 -
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04031534 -
Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
Terminated |
NCT02552550 -
Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
|
||
Active, not recruiting |
NCT04398524 -
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
|
Phase 2 | |
Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
Completed |
NCT01663259 -
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
|
N/A | |
Not yet recruiting |
NCT05962242 -
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06061705 -
Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
|
N/A | |
Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112535 -
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
|
N/A | |
Completed |
NCT01921426 -
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
|
Phase 1 | |
Completed |
NCT01181648 -
Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
|
||
Recruiting |
NCT05918510 -
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
|
||
Recruiting |
NCT05894083 -
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
|
Phase 2 |